

ValÃ©ria Valim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2693980/publications.pdf>

Version: 2024-02-01

63
papers

1,717
citations

394421

19
h-index

289244

40
g-index

67
all docs

67
docs citations

67
times ranked

2040
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. <i>Rheumatology</i> , 2022, 62, 243-255.	1.9	12
2	Recommendations for evaluation and diagnosis of extra-glandular manifestations of primary sjogren syndrome: results of an epidemiologic systematic review/meta-analysis and a consensus guideline from the Brazilian Society of Rheumatology (articular, pulmonary and renal). <i>Advances in Rheumatology</i> , 2022, 62, .	1.7	4
3	Health-related quality of life and costs in Sjögren's syndrome. <i>Rheumatology</i> , 2021, 60, 2588-2601.	1.9	31
4	SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients. <i>Rheumatology</i> , 2021, 60, 2946-2957.	1.9	15
5	Pain and fatigue are predictors of quality of life in primary Sjögren's syndrome. <i>Advances in Rheumatology</i> , 2021, 61, 28.	1.7	8
6	Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination. <i>Scientific Reports</i> , 2021, 11, 10431.	3.3	3
7	CCL3, CCL5, IL-15, IL-1Ra and VEGF compose a reliable algorithm to discriminate classes of adverse events following 17DD-YF primary vaccination according to cause-specific definitions. <i>Vaccine</i> , 2021, 39, 4359-4372.	3.8	4
8	Understanding Fatigue in Sjögren's Syndrome: Outcome Measures, Biomarkers and Possible Interventions. <i>Frontiers in Immunology</i> , 2021, 12, 703079.	4.8	12
9	2021 recommendations of the Brazilian Society of Rheumatology for the gynecological and obstetric care of patients with Sjogren's syndrome. <i>Advances in Rheumatology</i> , 2021, 61, 54.	1.7	7
10	Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil. <i>Advances in Rheumatology</i> , 2021, 61, 60.	1.7	5
11	Parotid gland swelling in primary Sjögren's syndrome: activity and other sialadenosis causes. <i>Rheumatology</i> , 2021, , .	1.9	0
12	Incidence and risk factors for moderate/severe COVID-19 in rheumatic diseases patients on hydroxychloroquine: a 24-week prospective cohort. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	1
13	Post-COVID-19 syndrome in patients with primary Sjögren's syndrome after acute SARS-CoV-2 infection. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
14	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 166-174.	0.8	12
15	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium.. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 133, 166-174.	0.8	0
16	Incidence of Infectious Adverse Events in Patients With Rheumatoid Arthritis and Spondyloarthritis on Biologic Drugs—Data From the Brazilian Registry for Biologics Monitoring. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 73-78.	0.9	11
17	Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome. <i>Rheumatology</i> , 2020, 59, 2350-2359.	1.9	54
18	Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study. <i>Frontiers in Immunology</i> , 2020, 11, 1382.	4.8	16

#	ARTICLE	IF	CITATIONS
19	Acinar adipose tissue infiltration in salivary gland biopsy is associated with kynurenines-Interferon- $\hat{3}$ pathway inflammation biomarkers. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 27-33.	0.8	3
20	Systemic phenotype related to primary SjÃ©gren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 85-94.	0.8	2
21	<p>Managing fatigue in patients with primary Sjögren’s syndrome: challenges and solutions</p>. <i>Open Access Rheumatology: Research and Reviews</i> , 2019, Volume 11, 77-88.	1.6	19
22	Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR. <i>Clinical Rheumatology</i> , 2019, 38, 2129-2139.	2.2	8
23	Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases. <i>Advances in Rheumatology</i> , 2019, 59, 17.	1.7	18
24	Recommendations from the Brazilian society of rheumatology for the diagnosis of SjÃ©gren's syndrome (Part I): glandular manifestations (systematic review). <i>Advances in Rheumatology</i> , 2019, 59, 58.	1.7	13
25	Yellow Fever Virus Genotyping Tool and Investigation of Suspected Adverse Events Following Yellow Fever Vaccination. <i>Vaccines</i> , 2019, 7, 206.	4.4	6
26	Chronic Inflammatory Arthropathy Preceding Acute Systemic Manifestations of Sarcoidosis: A Possible Overlap of Idiopathic Juvenile Arthritis and Sarcoidosis. <i>Case Reports in Rheumatology</i> , 2019, 2019, 1-8.	0.6	1
27	Supervised walking improves cardiorespiratory fitness, exercise tolerance, and fatigue in women with primary SjÃ©gren's syndrome: a randomized-controlled trial. <i>Rheumatology International</i> , 2019, 39, 227-238.	3.0	20
28	Systemic manifestations of primary SjÃ©gren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 97-106.	0.8	6
29	Neurological and Inflammatory Manifestations in SjÃ©gren's Syndrome: The Role of the Kynurenine Metabolic Pathway. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3953.	4.1	29
30	Pulmonary paracoccidioidomycosis: a case report of reactivation in a patient receiving biological therapy. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2018, 51, 249-252.	0.9	12
31	Posterior reversible encephalopathy syndrome during treatment with tocilizumab in juvenile idiopathic arthritis. <i>Arquivos De Neuro-Psiquiatria</i> , 2018, 76, 720-721.	0.8	17
32	Do antimalarials protect against damage accrual in primary SjÃ©gren's syndrome? Results from a Latin-American retrospective cohort. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 182-185.	0.8	1
33	How immunological profile drives clinical phenotype of primary SjÃ©gren's syndrome at diagnosis: analysis of 10,500 patients (SjÃ©gren Big Data Project). <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 102-112.	0.8	37
34	Influence of geolocation and ethnicity on the phenotypic expression of primary SjÃ©gren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data SjÃ©gren Project Consortium. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1042-1050.	0.9	132
35	IncidÃ©ncia de tuberculose em pacientes com artrite reumatoide em uso de bloqueadores do TNF no Brasil: dados do Registro Brasileiro de MonitoraÃ©o de Terapias BiolÃ³gicas BiobadaBrasil. <i>Revista Brasileira De Reumatologia</i> , 2017, 57, 477-483.	0.8	28
36	Incidence of tuberculosis among patients with rheumatoid arthritis using TNF blockers in Brazil: data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62	0.7	19

#	ARTICLE	IF	CITATIONS
37	Defining disease activity states and clinically meaningful improvement in primary SjÅ¶gren's syndrome with EULAR primary SjÅ¶gren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 382-389.	0.9	225
38	Antibodies against carbamylated proteins are present in primary SjÅ¶gren's syndrome and are associated with disease severity. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1494-1500.	0.9	39
39	Atherosclerosis in SjÅ¶gren's syndrome: evidence, possible mechanisms and knowledge gaps. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 133-42.	0.8	10
40	Serum calprotectin is a biomarker of carotid atherosclerosis in patients with primary SjÅ¶gren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 1006-1012.	0.8	6
41	ValidaÃ§Ã£o e propriedades psicomÃ©tricas do Eular SjÅ¶gren's Syndrome Patient Reported Index (ESSPRI) para a lÃngua portuguesa. <i>Revista Brasileira De Reumatologia</i> , 2015, 55, 439-445.	0.8	12
42	AvaliaÃ§Ã£o e tratamento da sÃndrome de SjÅ¶gren em foco. <i>Revista Brasileira De Reumatologia</i> , 2015, 55, 396-397.	0.8	2
43	Validation and psychometric properties of the EULAR SjÅ¶gren's Syndrome Patient Reported Index (ESSPRI) into Brazilian Portuguese. <i>Revista Brasileira De Reumatologia</i> , 2015, 55, 439-445.	0.7	3
44	Clinical characteristics and biopsy accuracy in suspected cases of SjÅ¶gren's syndrome referred to labial salivary gland biopsy. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 30.	1.9	39
45	Assessment of fatigue and dryness in primary SjÅ¶gren's syndrome: Brazilian version of "Profile of Fatigue and Discomfort - Sicca Symptoms Inventory (short form) (PROFAD-SSI-SF)". <i>Revista Brasileira De Reumatologia</i> , 2015, 55, 113-122.	0.7	1
46	Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL. <i>Clinical Rheumatology</i> , 2015, 34, 921-927.	2.2	35
47	Recommendations for the treatment of SjÅ¶gren's syndrome. <i>Revista Brasileira De Reumatologia</i> , 2015, 55, 446-457.	0.7	1
48	RecomendaÃ§Ãµes para o tratamento da sÃndrome de SjÅ¶gren. <i>Revista Brasileira De Reumatologia</i> , 2015, 55, 446-457.	0.8	17
49	AvaliaÃ§Ã£o da fadiga e da secura na sÃndrome de SjÅ¶gren primÃ¡ria: versÃ£o brasileira do "Profile of Fatigue and Discomfort - Sicca Symptoms Inventory (short form) (Profad-SSI-SF)". <i>Revista Brasileira De Reumatologia</i> , 2015, 55, 113-122.	0.8	14
50	Validation of EULAR primary SjÅ¶gren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 859-866.	0.9	193
51	Current Approach to Dry Eye Disease. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 49, 288-297.	6.5	51
52	Strengthening Exercises Improve Symptoms and Quality of Life but Do Not Change Autonomic Modulation in Fibromyalgia: A Randomized Clinical Trial. <i>PLoS ONE</i> , 2014, 9, e90767.	2.5	73
53	Transcultural adaptation of the "EULAR SjÅ¶gren's Syndrome Disease Activity Index (ESSDAI)" into Brazilian Portuguese. <i>Revista Brasileira De Reumatologia</i> , 2013, 53, 483-493.	0.7	2
54	Effects of physical exercise on serum levels of serotonin and its metabolite in fibromyalgia: a randomized pilot study. <i>Revista Brasileira De Reumatologia</i> , 2013, 53, 538-541.	0.7	3

#	ARTICLE	IF	CITATIONS
55	Adapta�o transcultural do �EULAR Sj�gren's Syndrome Disease Activity Index (ESSDAI)� para a �ngua portuguesa. Revista Brasileira De Reumatologia, 2013, 53, 483-493.	0.8	19
56	Primary Sj�gren's syndrome prevalence in a major metropolitan area in Brazil. Revista Brasileira De Reumatologia, 2013, 53, 24-34.	0.7	9
57	Primary Sj�gren's syndrome prevalence in a major metropolitan area in Brazil. Revista Brasileira De Reumatologia, 2013, 53, 24-34.	0.8	4
58	Intensity level for exercise training in fibromyalgia by using mathematical models. BMC Musculoskeletal Disorders, 2010, 11, 54.	1.9	18
59	Cognitive Behavioral Therapy for the Treatment of Fibromyalgia Syndrome: A Randomized Controlled Trial. Journal of Musculoskeletal Pain, 2008, 16, 133-140.	0.3	24
60	A randomized controlled trial of deep water running: Clinical effectiveness of aquatic exercise to treat fibromyalgia. Arthritis and Rheumatism, 2006, 55, 57-65.	6.7	152
61	Aerobic fitness effects in fibromyalgia. Journal of Rheumatology, 2003, 30, 1060-9.	2.0	130
62	Peak oxygen uptake and ventilatory anaerobic threshold in fibromyalgia. Journal of Rheumatology, 2002, 29, 353-7.	2.0	51
63	Incidence and risk factors for moderate/severe COVID-19 in rheumatic diseases patients on hydroxychloroquine: a 24-week prospective cohort. Clinical and Experimental Rheumatology, 0, , .	0.8	1